<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a kind of clonal stem-cell disorder in which aberration within a hematopoietic stem cell (<z:chebi fb="15" ids="50443">HSC</z:chebi>) gives rise to the entire disease as in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Studies have showed that contrasting <z:mpath ids='MPATH_458'>normal</z:mpath> stem cells, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> stem cells express CD96 and CD123, but lack of CD90, although both of them reside within the CD34(+)CD38(-) population </plain></SENT>
<SENT sid="2" pm="."><plain>So far, little is known about expression of the markers on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:chebi fb="15" ids="50443">HSC</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we analyzed the immunophenotypic characteristics of CD34(+)CD38(-) bone marrow (BM) cells by multicolor flow cytometry in 38 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 10 control patients </plain></SENT>
<SENT sid="4" pm="."><plain>We found that CD34(+)CD38(-) BM cells coexpressed CD13, CD33, CD117, CD133, and HLA-DR almost in <z:hpo ids='HP_0000001'>all</z:hpo> patients, but in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> they expressed higher amounts of CD13 (79% +/- 16% vs. 36% +/- 13%, P &lt; 0.05) and CD133 (66% +/- 20% vs. 25% +/- 13%, P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>CD90 was expressed in <z:hpo ids='HP_0000001'>all</z:hpo> control patients but just in 63% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>No control patients had an expression of CD2, CD5, CD7, CD44, CD96, and CD123, which expressed variable amounts in 17-53% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The level of CD13 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> (89% +/- 7%), <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e> (88% +/- 11%), and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e> (81% +/- 13%) were obviously higher than that of RA (63% +/- 16%, P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>CD2, CD5, and CD7 were more frequently observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> or INT and HIGH-R cases </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, we demonstrate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> stem cells display deranged <z:hpo ids='HP_0000118'>phenotypic abnormalities</z:hpo> that may make them particularly difficult to eradicate using therapies targeted against surface antigens, and the percentage of cells expressing CD13 is notably higher in patients with high-grade <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> that may be a potential prognostic indicator of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in the future </plain></SENT>
</text></document>